Ciloa has developed the sole technology to produce all types of complex membrane proteins on exosomes. This allows to work with the families of membrane proteins that are called “undruggable”, but that are also the most promising therapeutic targets. Of these are the GPCRs (G-protein coupled receptors), and the ion channels .
OVERCOME UNDRUGGABLE MEMBRANE PROTEINS
Viral envelope proteins
G-protein coupled receptors
Ion channels
Kinase receptors
IG Superfamily
MAIN TARGETS OF CURRENT AND FUTURE DRUGS
Ciloa produces native transmembrane proteins, such as receptors (GPCR, Receptor Kinases), ion channels, transporters, viral envelope proteins. These proteins may have one or several transmembrane domains and can be produced as monomers, homo-oligomers or hetero-oligomers.
STRATEGIC MEMBRANE PROTEINS
The transmission of signals and metabolites across the membrane of all organisms is absolutely necessary for their life and survival.
Membrane proteins are responsible for these vital connections between the internal and external environments. Because of their strategic location they are the main targets of current and future drugs used in prevention and therapies.
MULTI-TRANSMEMBRANE PROTEINS
Transmembrane proteins are embedded in the lipid bilayer of membranes. They differ according to their topology, their oligomerization status, and their functions.
Membrane proteins may have a single-transmembrane domain or multi-transmembrane domains. Due to their high hydrophobicity, multi-transmembrane proteins are the most difficult to produce out of cells.
TRANSPORTERS, ION CHANNELS, RECEPTORS
Membrane proteins play roles in adhesion, transport, signal transduction and more.
Due to their crucial physiological functions, the most promising therapeutic targets are the receptors that belong to the G-protein coupled receptor (GPCR), receptor kinase and ion channel classes.